Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 778M 709M 653M 594M 1.11B 72.05B 1.17B 7.95B 3.16B 39.35B 2.92B 2.86B 124B P/E 2026 *
3.61x
P/E 2027 * 3.46x
Enterprise Value 778M 709M 653M 594M 1.11B 72.05B 1.17B 7.95B 3.16B 39.35B 2.92B 2.86B 124B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.54x
Free-Float
96.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.21%
1 week-2.69%
Current month+34.29%
1 month+29.48%
3 months+13.53%
6 months+19.90%
Current year+39.47%
1 week 4.56
Extreme 4.555
4.94
1 month 3.38
Extreme 3.38
5
Current year 2.95
Extreme 2.95
5.78
1 year 2.95
Extreme 2.95
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 2021-03-11
Director of Finance/CFO 44 2026-05-14
Chief Tech/Sci/R&D Officer - 2026-07-19
Director TitleAgeSince
Director/Board Member 68 2021-06-03
Chairman 61 2019-03-31
Director/Board Member 56 2019-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Director

3,694 0.0022%
7/20/26 Free

Chief Technology Officer

137,036 0.0832%
7/7/26 Sell

Chief Financial Officer

-127,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-2.69%+48.26%-50.58% 776M
-0.30%-6.68%+29.12%+125.42% 1,200B
+1.25%-5.35%+33.19%+80.42% 651B
+0.94%-2.99%+24.73%+106.93% 506B
-0.60%-1.95%+27.26%+67.32% 377B
+0.69%-9.50%+40.80%+30.23% 330B
+0.41%-4.70%+27.23%+51.59% 288B
+0.81%-4.08%-1.74%+32.71% 272B
-0.15%-6.45%+29.63%+64.18% 236B
-0.06%-0.98%+33.15%+118.99% 206B
Average +0.31%-4.55%+29.16%+62.72% 407B
Weighted average by Cap. +0.40%-5.19%+28.04%+87.47%

Financials

2026 *2027 *
Net sales 494M 450M 414M 377M 707M 45.71B 743M 5.04B 2B 24.97B 1.85B 1.81B 78.36B 504M 459M 423M 385M 722M 46.69B 759M 5.15B 2.05B 25.5B 1.89B 1.85B 80.04B
Net income 217M 198M 182M 166M 311M 20.1B 327M 2.22B 881M 10.98B 814M 797M 34.46B 236M 215M 198M 180M 338M 21.88B 356M 2.41B 959M 11.95B 886M 868M 37.5B
Net Debt - -
Projected Income Statement - Annual - Ironwood Pharmaceuticals, Inc.
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
26-11-20 $4.700 -0.21% 3,021,738
26-11-19 $4.710 -1.46% 3,292,359
26-11-18 $4.780 -1.85% 2,217,541
26-11-17 $4.870 +0.41% 2,824,897
26-11-16 $4.850 +0.41% 3,109,430
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ironwood Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.700USD
Average target price
6.175USD
Spread / Average Target
+31.38%
  1. Stock Market
  2. Stocks
  3. IRWD Stock